Skip to main content
Premium Trial:

Request an Annual Quote

Decode Reports 20-Percent Jump in Q3 Revenue, Narrowed Losses; R&D Spend Surges 70 Percent

NEW YORK, Nov. 8 (GenomeWeb News) - Decode Genetics yesterday reported a 20-percent increase in revenues amid narrowed losses for the third quarter.

 

Decode's revenues for the third quarter rose to $13.2 million from $11 million in the same period a year ago.

 

The company said R&D spending in the quarter surged nearly 70 percent to $11 million from $6.5 million for the same quarter last year.

 

Decode narrowed its net losses this quarter by 8.8 percent to $11.4 million, or $.21 per basic share, from $12.5 million, or $.23 per basic share in the year-ago period.

 

Qiagen had approximately $171 million in cash and cash investments as of Sept. 30.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.